Risks of inadvertently active placebo in randomized trials: an overlooked cause of inconsistency.

Medicina (B Aires)

Escuela de Medicina, Facultad de Medicina, Universidad del Salvador, Buenos Aires, Argentina. E-mail:

Published: November 2023

Download full-text PDF

Source

Publication Analysis

Top Keywords

risks inadvertently
4
inadvertently active
4
active placebo
4
placebo randomized
4
randomized trials
4
trials overlooked
4
overlooked inconsistency
4
risks
1
active
1
placebo
1

Similar Publications

Substandard and falsified (SF) medical products are a serious health and economic concern that disproportionately impact low- and middle-income countries and marginalized groups. Public education campaigns are demand-side interventions that may reduce risk of SF exposure, but the effectiveness of such campaigns, and their likelihood of benefitting everybody, is unclear. Nationwide pilot risk communication campaigns, involving multiple media, were deployed in Ghana, Nigeria, Sierra Leone, Uganda in 2020-2021.

View Article and Find Full Text PDF

Background: The Swedish COVID-19 strategy aimed to protect vulnerable groups through targeted measures, categorizing individuals aged 70 and above as high-risk. This study examines the impact of such group-based risk assessments on subjective health and virus-related concerns among older adults.

Methods: We analyzed survey data from the SOM Institute for 68- to 71-year-olds in 2019 (N = 684) and 2020 (N = 726).

View Article and Find Full Text PDF

The objective of this study was to investigate the characteristics and trends of therapeutic errors in non-healthcare facility settings associated with antithrombotic medications reported to United States Poison Centers by analyzing data from the National Poison Data System from 2000 to 2021. There were 57 288 reported therapeutic error-related exposures involving antithrombotic medications as the primary substance. The rate of therapeutic errors increased by 590.

View Article and Find Full Text PDF

Sofosbuvir as post-exposure prophylaxis for yellow fever-associated viscerotropic disease (YEL-AVD).

J Antimicrob Chemother

January 2025

Department of Infectious Diseases, Royal Free London NHS Foundation Trust, London, UK.

Objectives: Yellow fever-associated viscerotropic disease (YEL-AVD) is a rare but serious complication arising from administration of live-attenuated yellow fever vaccine to individuals with risk factors such as thymectomy. At present there is no evidence-based treatment, and case fatality rates are high. Sofosbuvir, an NS5B nucleotide inhibitor, has activity against yellow fever virus in vitro and in vivo.

View Article and Find Full Text PDF

Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!